EyePoint Pharmaceuticals (EYPT) Common Equity: 2011-2019
Historic Common Equity for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Mar 2019 value amounting to $19.9 million.
- EyePoint Pharmaceuticals' Common Equity rose 142.46% to $19.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $19.9 million, marking a year-over-year increase of 142.46%. This contributed to the annual value of $11.7 million for FY2018, which is 12.37% down from last year.
- Per EyePoint Pharmaceuticals' latest filing, its Common Equity stood at $19.9 million for Q1 2019, which was down 47.18% from $37.6 million recorded in Q4 2018.
- Over the past 5 years, EyePoint Pharmaceuticals' Common Equity peaked at $47.7 million during Q3 2018, and registered a low of $8.2 million during Q1 2018.
- Its 3-year average for Common Equity is $18.9 million, with a median of $12.5 million in 2017.
- In the last 5 years, EyePoint Pharmaceuticals' Common Equity plummeted by 55.31% in 2015 and then skyrocketed by 430.00% in 2018.
- EyePoint Pharmaceuticals' Common Equity (Quarterly) stood at $14.4 million in 2015, then rose by 2.34% to $14.8 million in 2016, then crashed by 32.90% to $9.9 million in 2017, then spiked by 279.94% to $37.6 million in 2018, then spiked by 142.46% to $19.9 million in 2019.
- Its Common Equity was $19.9 million in Q1 2019, compared to $37.6 million in Q4 2018 and $47.7 million in Q3 2018.